Navigation Links
Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
Date:10/26/2007

WELLESLEY, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (Nasdaq: COLY), today announced that the company has received a $3.0 million milestone payment from GlaxoSmithKline (GSK) associated with the initiation of GSK's Phase III clinical trial in non-small cell lung cancer (NSCLC) of an immunotherapeutic cancer vaccine containing Coley's VaxImmune(TM) vaccine adjuvant.

In June 2007, GSK announced the launch of the largest Phase III clinical trial in lung cancer to evaluate the MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) in patients with early stage, completely resected NSCLC. VaxImmune is one of the components of MAGE-A3 ASCI, intended to increase an anti-tumor immune response. The randomized, double-blind, and placebo-controlled Phase III clinical trial, known as the MAGRIT trial (MAGE- A3 as Adjuvant Non-Small Cell Lung Cancer Immunotherapy) will target enrollment of about 2,270 patients with stage IB, II or IIIA resectable NSCLC. The primary endpoint of the trial is disease-free survival. The $3 million development milestone was triggered by the initiation of this Phase III trial.

VaxImmune is Coley's proprietary TLR9 agonist designed to induce both an enhanced antibody response and a potent killer T cell immune response when used in conjunction with vaccines in order to achieve and sustain a clinical response without compromising safety. Coley has granted GSK worldwide licenses for the use of VaxImmune in GSK's vaccines in development for certain cancers and infectious diseases.

About Coley Pharmaceutical Group

Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, asthma and allergy and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.

Safe Harbor Statement

Certain statements in this news release concerning Coley's business are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Coley might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; uncertainties as to the future success of ongoing and planned clinical trials; the risk that results from early stage clinical trials may not be indicative of results in later stage trials; the unproven safety and efficacy of products under development; intellectual property rights and litigation; competitive products; and other risks identified in Coley's filings with the Securities and Exchange Commission including, but not limited to, Coley's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Coley undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.


'/>"/>
SOURCE Coley Pharmaceutical Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... an immune response in pets such as canine, ... are of various types such as Attenuated Live ... Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live ... virus or bacteria, which have been weakend under ...
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, ... been honored by Enterprising Women magazine as one of its 2017 Enterprising Women ... business owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively ...
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist ... “I could have never imagined back in 1991 that this journey would have taken ... Over the last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into ...
(Date:4/26/2017)... ... April 26, 2017 , ... New ... profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively manage protein ... providing direct cost savings as well as more stable pricing over time. Now ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a leader ... in a new class of photodynamic cosmetics (PDC). , Allumera® is the first ... outward signs of aging, and minimize the appearance of pores – all with ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
Breaking Medicine News(10 mins):